CollPlant explores strategic options as revenue drops following milestone loss

CollPlant Biotechnologies (NASDAQ:CLGN) initiated a formal review of its strategic alternatives after a sharp contraction in milestone revenue caused its first-quarter sales to drop to near-zero, forcing the company to slash its workforce by half.

For the first quarter ended March 31, 2026, the regenerative medicine company reported GAAP revenue of $73,000, down from $2.1 million in the first quarter of 2025.

Management attributed the decline primarily to a non-recurring $2 million development milestone payment from a former business collaborator that had significantly boosted the prior-year period's figures.

The steep top-line contraction contributed to a widening bottom-line deficit.

CollPlant recorded a GAAP net loss of $3.1 million, or $0.23 per share, for the three-month period.

To protect its remaining capital reserves, the company implemented an aggressive cost-restructuring program, reducing its total headcount by approximately 50% to lower forward operating overhead.

The enterprise closed the first quarter with cash and cash equivalents of $4.3 million.

Capital reserves were supported by a registered direct equity offering completed in February 2026, which injected $1.7 million in net proceeds into the business.

In tandem with the operational downsizing, CollPlant’s executive leadership confirmed the commencement of a formal evaluation process to explore broader corporate paths.

Deputy Chief Executive Officer and Chief Financial Officer Eran Rotem stated that the company is assessing potential acquisitions, strategic corporate transactions, and other business combinations aimed at maximizing long-term shareholder value.

The company has not established a definitive timeline or committed to a specific transaction structure.

Despite the financial and corporate reorganizations, CollPlant continued to mark operational progression across its proprietary recombinant human collagen (rhCollagen) pipeline.

The company advanced its photocurable dermal filler program into the final phases of preclinical development.

It also secured a new patent from the Korean Intellectual Property Office protecting its light-activated aesthetic technologies.

Furthermore, the company expanded its commercial research portfolio with the official market launch of its BioFlex DLP bioprinting kit, targeting institutional laboratories specializing in 3D-bioprinted soft and hard tissue scaffolds.